Processing. Please wait...

## Amarin Probability Of Bankruptcy | $2.33 0.10 4.12% |

For stocks, Probability Of Bankruptcy is normalized value of Z-Score. For funds and ETFs it is derived from a multi-factor model developed by Macroaxis.The score is used to predict probability of a firm or a fund going into bankruptcy or experiencing financial distress within next 24 months. Unlike Z-Score, Probability Of Bankruptcy is the value between 0 and 100 indicating the actual probability the firm will be distressed in the next 2 fiscal years.

## About Probability Of Bankruptcy

Companies or funds with Probability Of Bankruptcy above 90% are generally considered to be high risk with a good chance of bankruptcy in the next 2 years. On the other hand entities with Probability Of Bankruptcy of less than 15% will most likely experience some growth in the next 2 years. Probability Of Bankruptcy is based on Macroaxis own algorithm and can be used by auditors, accountants, money managers, financial advisers, as well as day traders to evaluate unsystematic risk of a stock, fund or ETF.

## Amarin Probability Of Bankruptcy Assessment

## Filter other Stocks by Probability Of Bankruptcy

Amarin |
| = | 97.55 % |

Compare Amarin to competition |

Value |

Based on latest financial disclosure Amarin Corporation plc has Probability Of Bankruptcy of 97%. This is 141.1% higher than that of the Healthcare sector, and 62.99% higher than that of Drug Manufacturers - Other industry, The Probability Of Bankruptcy for all stocks is 126.91% lower than the firm.

Select Probability Of Bankruptcy Range |

Current Range |

Indicate Industry |

Click to run this filter | Filter Other Equities |

Found 10 equities | ## Probability Of Bankruptcy | ||

NVO | NYQ | Novo Nordisk AS | 1.0% |

TEVA | NYQ | Teva Pharmaceutical Industries Limited | 28.55% |

ENDP | NMS | Endo International plc | 39.11% |

RDY | NYQ | Dr Reddys Laboratories Ltd | 2.53% |

UTHR | NMS | United Therapeutics Corporation | 1.0% |

ISIS | NMS | Isis Pharmaceuticals Inc | 6.68% |

TARO | NYQ | Taro Pharmaceutical Industries Ltd | 1.0% |

DEPO | NMS | DepoMed Inc | 15.45% |

OREX | NMS | Orexigen Therapeutics Inc | 18.01% |

SCMP | NGM | Sucampo Pharmaceuticals Inc | 4.02% |

You can backtest this sub-set of assets as a synthetic portfolio or check its risk adjusted returns |

Amarin Corporation plc has **more than 97 (%) percent** chance of experiencing financial distress in the next 2 years of operations. More Info

Symbol | AMRN |

Name | Amarin Corporation plc |

Instrument | USA Stock |

Currency | USD - US Dollar |

Exchange | NASDAQ General Markets |

Description | Amarin Corporationration plc a biopharmaceutical company focuses on developing and commercializing therapeutics for the treatment of cardiovascular diseases in the United States.more |

Return On Asset | (28.32) % | ||

Profit Margin | (103.99) % | ||

Operating Margin | (177.03) % | ||

Current Valuation | 529.83 M | ||

Shares Outstanding | 174.59 M | ||

Shares Owned by Insiders | 3.93 % | ||

Shares Owned by Institutions | 33.30 % | ||

Number of Shares Shorted | 25.82 M | ||

Price to Earning | 291.00 times | ||

Price to Book | 341.94 times | ||

Price to Sales | 7.80 times | ||

Revenue | 54.2 M | ||

Gross Profit | 33.72 M | ||

EBITDA | (95.11 M) | ||

Net Income | (56.36 M) | ||

Cash and Equivalents | 119.54 M | ||

Cash per Share | 0.69 times | ||

Total Debt | 226.86 M | ||

Current Ratio | 3.60 times | ||

Book Value Per Share | (0.51) times | ||

Cash Flow from Operations | (72.31 M) | ||

Short Ratio | 4.10 times | ||

One Year High | 3.33 | ||

One Year Low | 0.78 | ||

Earnings Per Share | (0.36) times | ||

Price to Earnings To Growth | (0.05) times | ||

Number of Employees | 201 | ||

Beta | 0.35 | ||

Market Capitalization | 443.46 M | ||

Total Asset | 171.11 M | ||

Retained Earnings | (970.23 M) | ||

Working Capital | 104.98 M | ||

Current Asset | 145.28 M | ||

Current Liabilities | 40.31 M | ||

Z Score | -6.4 |